Background
==========

The hepatitis B virus (HBV) infection rate in systemic lupus erythematosus (SLE) patients has been investigated in various studies. Some earlier studies found a higher prevalence of hepatitis B surface antigen (HBsAg) in SLE patients \[[@b1-medscimonit-21-1955]--[@b3-medscimonit-21-1955]\], while others found a lower HBV infection rate in SLE patients \[[@b4-medscimonit-21-1955]--[@b7-medscimonit-21-1955]\]. Thus, it is deduced that HBV infection plays a protective role in the development of SLE.

HBV infection and SLE are age- and sex-specific. According to the Chinese national survey, the prevalence of HBV infection was higher in males than in females, and the highest prevalence before 1992 was in children \[[@b8-medscimonit-21-1955]\]. To control HBV infection, the national government implemented infant vaccination with a hepatitis B vaccine program since then. HBV infection was most prevalent in people aged 20--30 years old, as reported by the 2006 national survey \[[@b9-medscimonit-21-1955]\]. SLE is commonly seen in women of reproductive age. The female-to-male ratio was 10.1, the mean age at disease onset was 29.2 years old with confirmed diagnosis 1 year later at the age of 30.3 years old, according to multicenter research carried out by the Chinese SLE Treatment and Research Group \[[@b10-medscimonit-21-1955]\].

We therefore conducted this cross-sectional study to investigate the infection rate of HBV in SLE patients in China, and to determine the age and sex distribution of HBV infection in Chinese SLE patients.

Material and Methods
====================

Patients
--------

This is a cross-sectional study carried out in The First Affiliated Hospital of Sun Yat-sen University. We enrolled the patients who met these inclusion criteria: hospitalized patients diagnosed as SLE according to the American College of Rheumatology classification criteria for SLE revised in 1982 \[[@b11-medscimonit-21-1955]\] or 1997 \[[@b12-medscimonit-21-1955]\] from January 1, 1996 to December 31, 2011. The exclusion criteria were: (1) patients who had malignant diseases or drug-induced SLE; and (2) patients who did not demonstrate HBsAg.

Definitions of HBV infection
----------------------------

HBV infection was defined as positive for serological HBsAg according to the Guidelines of the National Medical Association Conference on Management of Chronic Hepatitis B \[[@b13-medscimonit-21-1955]\]. HBsAg, hepatitis B surface antibody (HBsAb) and hepatitis B core antibody (HBcAb) were detected by counter-immunoelectrophoresis on agarose gel from 1996 to 1997, and by enzyme-linked immunosorbent assay (ELISA) or chemiluminescence after 1997.

Ethics
------

This study was independently designed by the authors, conducted in compliance with the 1975 Declaration of Helsinki, and was approved by the Ethics Committee of The First Affiliated Hospital of Sun Yat-sen University.

Statistical analysis
--------------------

The categorical data were presented as numbers (in percent). The chi-square test or Fisher's exact test was used to analyze the categorical variables. The HBV infection rate in SLE patients was compared with the prevalence in 2006 national survey \[[@b9-medscimonit-21-1955]\], standardized to national census data in 2000. We compared 95% confidence intervals (95% CI) for the HBV infection rate of each variable; 95% CI which did not overlap were considered as statistically significant. Statistical analysis was performed using SPSS version 16.0 (SPSS for Windows; SPSS, Chicago, IL, USA). Statistical significance was considered as p\<0.05.

Results
=======

The infection rate of HBV
-------------------------

There were 4808 patients diagnosed as SLE in The First Affiliated Hospital of Sun Yat-sen University from January 1, 1996 to December 31, 2011, we excluded 803 patients who were not checked for serological HBsAg, 23 patients who were diagnosed with malignancy, and 1 patient who was diagnosed with drug-induced lupus. A total of 3981 patients were finally included in the analysis of HBV infection rate. The female-to-male ratio was 6.0 (3410/571) and the mean age was 31.1±14.5 years old in the investigated period. In the study population, 10.6% of patients were aged 0--14 years old, 77.6% were aged 15--49 years old, and 11.8% were aged 50 or older.

A total of 122 patients were positive for HBsAg at the first investigation. Thus, the HBV infection rate in this SLE cohort was 3.1%. Among them, the 118 patients who were tested for hepatitis B e antigen (HBeAg), the positive rate of HBeAg was 38.5% (45/118). There were 3809 patients with detected HBsAb and HBcAb in our SLE cohort. The positive rate of HBsAb was 60.1% (2289/3809), and for HBcAb was 25.8% (981/3809).

The age and sex distribution of HBV serological markers
-------------------------------------------------------

Because most of the SLE patients were women of reproductive age, the HBV infection rate was standardized by sex and age. As compared to the prevalence of HBV infection reported by the national survey in 2006, the sex-standardized HBV infection rate in adults aged 15--49 years old with SLE was lower, but there was no difference in children or adults older than 50 years old. Although the prevalence of HBV infection was higher in males than females in the general population (8.6% *vs.* 5.7%, p\<0.01), there was no difference between males and females among different age groups in the SLE population. The HBV infection rate in SLE patients standardized by age and sex was 3.3%, lower than that in the general population ([Table 1](#t1-medscimonit-21-1955){ref-type="table"}).

Similarly, the sex-standardized HBcAb positive rate was lower in adults aged 15--49 years old with SLE than in general population peers, but there was no difference in children and the elderly. And the positive rate of HBcAb was approximately the same between males and females (26.2% *vs.* 25.7%, p=0.780). The HBcAb positive rate in SLE patients standardized by age and sex was 26.1%, lower than that in the general population ([Table 2](#t2-medscimonit-21-1955){ref-type="table"}). Conversely, the HBsAb positive rate in SLE patients standardized by age and sex was 58.1%, higher than that in the general population, especially in patients aged 20--39 years old. The positive rate was higher in females than males (60.8% *vs.* 56.1%, p=0.042) ([Table 3](#t3-medscimonit-21-1955){ref-type="table"}).

Discussion
==========

In the present study, the HBV infection rate standardized by age and sex in SLE patients was 3.3%, which was much lower than the HBV infection prevalence of 7.18% to 9.75% obtained in the general population according to the Chinese national survey \[[@b8-medscimonit-21-1955],[@b9-medscimonit-21-1955]\]. Various studies mentioned the HBV infection rates in patients with SLE. Earlier studies indicated that the positive rates of HBsAg ranged from 25% to 70% in patients with SLE, and were higher than that in normal controls \[[@b1-medscimonit-21-1955]--[@b3-medscimonit-21-1955]\]. From the 1980s to present, studies reported the positive rates of HBsAg ranged from 1% to 3.5% in patients with SLE, which were lower or equal to that in normal controls \[[@b4-medscimonit-21-1955]--[@b7-medscimonit-21-1955]\]. Our present HBV infection rate was similar to the rate reported in Taiwan \[[@b6-medscimonit-21-1955]\]. The discrepancy among the studies might be due to different methods of detecting HBsAg in different races, and the different endemic situations of HBV infection around the world. Patients with HBV infection had higher concentrations of testosterone \[[@b14-medscimonit-21-1955]\], while SLE patients had lower testosterone levels, which partially explained the lower HBV infection rate in SLE patients. Based on the lower HBV infection rate in SLE patients, it was deduced that HBV infection played a protective role in the development of SLE. HBV induced host immunological tolerance by increasing the proportion of regulatory T cells (Tregs) in CD4 T cells in peripheral blood and maturation arrest of myeloid dendritic cells \[[@b15-medscimonit-21-1955]--[@b17-medscimonit-21-1955]\], all of which could prevent the occurrence and development of SLE. Another conceivable explanation for the lower HBV infection rate was that SLE protected subjects from HBV infection, probably due to high levels of INF-α \[[@b18-medscimonit-21-1955],[@b19-medscimonit-21-1955]\]. The HBcAb positive rate was also lower in SLE patients in our present study, consistent with the results of a study based on a northwestern Colombian population \[[@b20-medscimonit-21-1955]\]. The presence of HBcAb in serum implies previous or current infection with HBV. The lower HBcAb positive rate further confirms that HBV infection plays a protective role in the development of SLE and vice versa. Conversely, the positive rate of HBsAb was higher in SLE patients. Both HBsAb and HBcAb are immunoglobulin secreted by antigen-specific plasma cells, but are directed against different epitopes. Compared with HBcAb, HBsAb appears later, disappears earlier, and has lower titers in the host immune response to HBV. Unlike HBcAb, HBsAb is a neutralizing antibody that can clear HBV from the host. Thus, despite the 2 reasons mentioned above, the lower HBV infection rate might be attributed to the higher positive rate of HBsAb in SLE patients. HBsAb was detectable after vaccination or during convalescent phase. Hepatitis B vaccination was reported to be associated with increased risk of SLE \[[@b21-medscimonit-21-1955]--[@b23-medscimonit-21-1955]\]. It is speculated that HBV could induce an overly strong immune response in SLE patients, thus the virus is cleared thoroughly from SLE patients. However, it is still unknown whether the anti-virus immune response is antigen-specific or is just caused by high levels of INF-α.

In the general population, the prevalence of HBV infection is lower in females than males (5.7% *vs.* 8.6%) \[[@b9-medscimonit-21-1955]\]. However, in our cohort of SLE patients, there was no difference in HBV infection rate between males and females. We might have found a significant difference in a larger sample. The present study showed that although HBV infection was rare in patients with SLE, the infection rate in children was as high as that in general population peers \[[@b9-medscimonit-21-1955]\]. Compared with adult-onset SLE, pediatric SLE (pSLE) is characterized by more organ involvement and worse prognosis, but the reasons are still unknown. Intricacies of the developing immune system may partly account for the more severe phenotype in pSLE \[[@b24-medscimonit-21-1955]\]. The difference in HBV infection in adult-onset SLE and pSLE is merely a small part of the difference in immune pathogenesis between the 2 groups.

Conclusions
===========

We found a lower HBV infection rate and HBcAb positive rate in SLE patients aged 15--49 years old compared with the general population. Thus, we deduced that HBV infection protected subjects from SLE and vice versa. Unlike in the general population, there were no difference in HBV infection rate between males and females. There were several limitations of this study. First, this was a cross-sectional study, and we cannot know whether the discrepancy in HBV infection rate among different age groups was due to different immune status of pSLE and late-onset SLE or if it was just a coincidence. Second, the HBV infection rate was compared with data from the national survey, not an exactly matched sample of the general population, which caused bias.
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###### 

Age distribution of HBsAg in SLE patients.

  Age group, yrs   No. of SLE (total)   No. of SLE (male/female)   HBV infection rate in SLE, %   Sex-standardized HBV infection rate in SLE, % (95% CI)   Sex-standardized prevalence of HBsAg found in 2006 national survey, % (95% CI)^9^                                                                            
  ---------------- -------------------- -------------------------- ------------------------------ -------------------------------------------------------- ----------------------------------------------------------------------------------- ------------------------------------------------------------------------ --------------------
  0--14            421                  80/341                     5.0                            1.8                                                      0.192                                                                               3.5 (0.9--6.1)                                                           1.9 (1.8--2.0)
  15--19           499                  85/414                     0.0                            2.7                                                      0.265                                                                               1.3 (0.5--2.0)[\*](#tfn1-medscimonit-21-1955){ref-type="table-fn"}       5.4 (4.4--6.4)
  20--29           1165                 125/1040                   4.8                            2.2                                                      0.147                                                                               3.5 (1.6--5.4)[\*](#tfn1-medscimonit-21-1955){ref-type="table-fn"}       10.5 (8.2--12.7)
  30--39           900                  92/808                     4.3                            2.8                                                      0.633                                                                               3.6 (1.4--5.8)[\*](#tfn1-medscimonit-21-1955){ref-type="table-fn"}       8.6 (7.5--9.6)
  40--49           527                  70/457                     2.9                            3.9                                                      0.916                                                                               3.4 (1.2--5.6)[\*](#tfn1-medscimonit-21-1955){ref-type="table-fn"}       8.5 (7.4--9.6)
  50--59           285                  59/226                     10.2                           4.9                                                      0.126                                                                               8.2 (3.8--12.6)                                                          8.9 (7.1--10.7)
  60--100          184                  60/124                     3.3                            4.8                                                      0.933                                                                               4.1 (1.2--7.0)                                                           --
  **Total**        **3981**             **571/3410**               **4.2**                        **2.8**                                                  **0.088**                                                                           **3.7 (2.8--4.7)**[\*](#tfn1-medscimonit-21-1955){ref-type="table-fn"}   **7.2 (6.7--7.7)**

HBV infection rate was significantly lower than that in the general population.

###### 

Age distribution of HBcAb in SLE patients.

  Age group, yrs   No. of SLE (total)   No. of SLE (male/female)   HBcAb positive rate in SLE, %   Sex-standardized HBcAb positive rate in SLE, % (95% CI)   Sex-standardized prevalence of HBcAb found in 2006 national survey, % (95% CI)^9^                                                                               
  ---------------- -------------------- -------------------------- ------------------------------- --------------------------------------------------------- ----------------------------------------------------------------------------------- --------------------------------------------------------------------------- ------------------------------------------------------------------------
  0--14            401                  73/328                     11.0                            10.7                                                      0.943                                                                               10.8 (6.7--14.9)                                                            10.7 (9.7--11.7)[\*\*](#tfn3-medscimonit-21-1955){ref-type="table-fn"}
  15--19           472                  79/393                     10.1                            18.7                                                      0.085                                                                               14.0 (10.1--17.9)[\*](#tfn2-medscimonit-21-1955){ref-type="table-fn"}       25.0 (22.3--27.7)
  20--29           1115                 123/992                    22.8                            25.9                                                      0.451                                                                               24.3 (20.3--28.3)[\*](#tfn2-medscimonit-21-1955){ref-type="table-fn"}       38.9 (36.6--41.3)
  30--39           859                  90/769                     28.9                            26.9                                                      0.691                                                                               27.9 (22.3--33.0)[\*](#tfn2-medscimonit-21-1955){ref-type="table-fn"}       41.8 (39.3--44.3)
  40--49           513                  69/444                     33.3                            32.4                                                      0.882                                                                               32.9 (26.8--39.0)[\*](#tfn2-medscimonit-21-1955){ref-type="table-fn"}       45.1 (42.7--47.5)
  50--59           272                  54/218                     46.3                            39.4                                                      0.359                                                                               43.0 (35.4--50.6)                                                           50.0 (46.6--53.4)
  60--100          177                  57/120                     43.9                            31.7                                                      0.113                                                                               37.6 (30.0--45.2)                                                           --
  **Total**        **3809**             **545/3264**               **26.2**                        **25.7**                                                  **0.780**                                                                           **26.1 (24.0--28.1)**[\*](#tfn2-medscimonit-21-1955){ref-type="table-fn"}   **34.1 (32.8--35.5)**

HBcAb positive rate was significantly lower than that in the general population;

HBcAb positive rate of the general population aged 10--14 yrs.

###### 

Age distribution of HBsAb in SLE patients.

  Age group, yrs   No. of SLE (total)   No. of SLE (male/female)   HBsAb positive rate in SLE, %   Sex-standardized HBsAb positive rate in SLE, % (95% CI)   Sex-standardized prevalence of HBsAb found in 2006 national survey, % (95% CI)^9^                                                                               
  ---------------- -------------------- -------------------------- ------------------------------- --------------------------------------------------------- ----------------------------------------------------------------------------------- --------------------------------------------------------------------------- -------------------------------------------------------------------------
  0--14            401                  73/328                     65.9                            63.1                                                      0.671                                                                               64.5 (58.3--70.8)                                                           57.5 (55.4--59.5)[\*\*](#tfn5-medscimonit-21-1955){ref-type="table-fn"}
  15--19           472                  79/393                     51.9                            66.4                                                      0.014                                                                               59.0 (52.9--65.1)                                                           50.3 (44.4--56.2)
  20--29           1115                 123/992                    57.7                            65.1                                                      0.106                                                                               61.3 (56.7--66.0)[\*](#tfn4-medscimonit-21-1955){ref-type="table-fn"}       45.6 (42.9--48.4)
  30--39           859                  90/769                     56.7                            58.6                                                      0.718                                                                               57.6 (52.1--63.2)[\*](#tfn4-medscimonit-21-1955){ref-type="table-fn"}       46.4 (44.1--48.7)
  40--49           513                  69/444                     53.6                            52,7                                                      0.887                                                                               53.2 (46.7--50.0)                                                           46.0 (43.5--48.5)
  50--59           272                  54/218                     51,9                            56,4                                                      0.545                                                                               54.1 (46.5--61.7)                                                           50.3 (47.2--53.5)
  60--100          177                  57/120                     52.6                            50.8                                                      0.823                                                                               51.7 (43.9--59.5)                                                           --
  **Total**        **3809**             **545/3264**               **56.1**                        **60.8**                                                  **0.042**                                                                           **58.1 (55.7--60.4)**[\*](#tfn4-medscimonit-21-1955){ref-type="table-fn"}   **50.1 (48.8--51.3)**

HBsAb positive rate was significantly higher than that in the general population;

HBsAb positive rate of the general population aged 10--14 yrs.

[^1]: Study Design

[^2]: Data Collection

[^3]: Statistical Analysis

[^4]: Data Interpretation

[^5]: Manuscript Preparation

[^6]: Literature Search

[^7]: Funds Collection
